Hepatic Encephalopathy Epidemiology Forecast

DelveInsight’s ‘Hepatic Encephalopathy—Epidemiology Forecast–2030’ report delivers an in-depth understanding of the disease, historical and forecasted Hepatic Encephalopathy epidemiology in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2018–2030

Hepatic Encephalopathy Understanding

Hepatic encephalopathy is a brain disorder that develops in some individuals with liver disease. It is a complex disorder that encompasses a spectrum or continuum of disease that ranges from a subtle condition with no outward signs or symptoms to a severe form that can cause serious, life-threatening complications. Hepatic encephalopathy can occur in individuals with acute or chronic liver (hepatic) disease or in individuals whose liver is bypassed by a portosystemic shunt (with no liver disease present). A portosystemic shunt is an abnormal passageway that allows blood from the gastrointestinal tract to bypass the liver. They can be present at birth (congenital) or acquired during life. Hepatic encephalopathy is caused when toxins that are normally cleared from the body by the liver accumulate in the blood, eventually traveling to the brain.


It is manifested by the broad spectrum of neuropsychiatric disturbances such as defects in cognitive, emotional, behavioral, psychomotor, and locomotive functions. This condition is characterized by personality changes, intellectual impairment, and a depressed level of consciousness. The prerequisite for the syndrome is a diversion of portal blood into the systemic circulation through portosystemic collateral vessels. In patients with cirrhosis, an acute encephalopathy is most commonly associated with a precipitating factor, such as electrolyte disturbance, medications, gastrointestinal hemorrhage, or infection.

Hepatic Encephalopathy Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Number of Hepatic Encephalopathy Cases, Gender-specific Cases of Hepatic Encephalopathy, Age-Specific Cases of Hepatic Encephalopathy, and Type-Specific Cases of Hepatic Encephalopathy scenario of Hepatic Encephalopathy in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2018 to 2030.

Hepatic Encephalopathy Detailed Epidemiology Segmentation

  • The total number of cases of Hepatic Encephalopathy (HE) in the 7MM was estimated to be approximately 856,610 in 2020.
  • Among 7MM, the United States has the highest number of cases of Hepatic Encephalopathy with about 595,090 cases in 2020.
  • DelveInsight’s estimations suggest that the majority of cases of Hepatic Encephalopathy are males as compared to females. There was a total of around 432,631 male and approximately 162,460 female cases of Hepatic Encephalopathy in 2020 in the United States.
  • The age‐specific data revealed that the highest number of Hepatic Encephalopathy people affected with was found in the age group of 45–54 years, while people <25 years are the least affected. There were a total of 17,853, 30,350, 96,405, 246,367, 126,159, 35,705, and 42,251 age-specific cases of Hepatic Encephalopathy in the age‐group <25 years, 25–34 years, 35–44 years, 45–54 years, 55–64 years, 65–74 years, and 75+ years in 2020 in the United States.
  • In 2020, it was found that there were 357,054 cases of covert HE, and 238,036 cases of overt HE in the United States.
  • In 2020 among EU-5 countries, the United Kingdom had the highest number of cases with approximately 56,099 followed by Germany with approximately 53,878 cases and France with about 44,857 cases. While Spain has the least number of cases with approximately 18,715.
  • In 2020, the number of cases of Hepatic encephalopathy in Japan was found to be approximately 47,873 holding the fourth-largest epidemiology share in 7MM.

Scope of the Report

  • The report covers the descriptive overview of Hepatic Encephalopathy, explaining its causes, signs, and symptoms, and pathophysiology.
  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan.
  • The report assesses the disease risk and burden.
  • The report provides the segmentation of the disease epidemiology for 7MM by Number of Hepatic Encephalopathy Cases, Gender-specific Cases of Hepatic Encephalopathy, Severity-specific Cases of Hepatic Encephalopathy, and Type-specific Cases of Hepatic Encephalopathy.

Report Highlights

  • 10-Year Forecast of Hepatic Encephalopathy
  • 7MM Coverage
  • Number of Hepatic Encephalopathy Cases
  • Gender-specific Hepatic Encephalopathy Cases
  • Severity-specific Hepatic Encephalopathy Cases
  • Type-specific Hepatic Encephalopathy Cases

Key Questions Answered

  • What are the disease risk, burdens, and unmet needs of Hepatic Encephalopathy?
  • What is the historical Hepatic Encephalopathy patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
  • What would be the forecasted patient pool of Hepatic Encephalopathy at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Hepatic Encephalopathy?
  • Out of the countries mentioned above, which country would have the highest patient population of Hepatic Encephalopathy during the forecast period (2021–2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2021–2030)?

Reasons to buy

The Hepatic Encephalopathy report will allow the user to:

  • Develop business strategies by understanding the epidemiological trends of Hepatic Encephalopathy in the 7MM.
  • Quantify patient populations in the 7MM to improve product design, pricing, and launch plans.
  • The Hepatic Encephalopathy epidemiology report and model were written and developed by Masters and PhD level epidemiologists.
  • The Hepatic Encephalopathy epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 10-year forecast period using reputable sources.

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights

2. Report Introduction

3. Hepatic Encephalopathy (HE) Epidemiology Overview at a Glance

3.1. Epidemiology Share (%) of Hepatic Encephalopathy (HE) in 2018

3.2. Epidemiology Share (%) of Hepatic Encephalopathy (HE) in 2030

4. Executive Summary of Hepatic Encephalopathy (HE)

5. Disease Background and Overview

5.1. Introduction

5.2. Classification of Hepatic Encephalopathy

5.3. Symptoms of Hepatic Encephalopathy

5.4. Cause and risk factors of Hepatic Encephalopathy

5.5. Pathophysiology

5.6. Pathogenesis of Hepatic Encephalopathy

5.7. Diagnosis

5.7.1. The differential diagnosis for Hepatic Encephalopathy

5.7.2. Hepatic encephalopathy 2018: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF)

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. Methodology

6.3. Total Number of Hepatic Encephalopathy Cases in the 7MM

6.4. The United States

6.4.1. Assumptions and Rationale

6.4.2. Total Number of Hepatic Encephalopathy Cases in the United States

6.4.3. Gender-specific Cases of Hepatic Encephalopathy in the United States

6.4.4. Age-Specific Cases of Hepatic Encephalopathy in the United States

6.4.5. Type-Specific Cases of Hepatic Encephalopathy in the United States

6.5. EU5

6.5.1. Germany

6.5.1.1. Assumptions and Rationale

6.5.1.2. Total Number of Hepatic Encephalopathy Cases in Germany

6.5.1.3. Gender-Specific Cases of Hepatic Encephalopathy in Germany

6.5.1.4. Age-Specific Cases of Hepatic Encephalopathy in Germany

6.5.1.5. Type-Specific Cases of Hepatic Encephalopathy in Germany

6.5.2. France

6.5.2.1. Assumptions and Rationale

6.5.2.2. Total Number of Hepatic Encephalopathy Cases in France

6.5.2.3. Gender-Specific Cases of Hepatic Encephalopathy in France

6.5.2.4. Age-Specific Cases of Hepatic Encephalopathy in France

6.5.2.5. Type-Specific Cases of Hepatic Encephalopathy in France

6.5.3. Italy

6.5.3.1. Assumptions and Rationale

6.5.3.2. Total Number of Hepatic Encephalopathy Cases in Italy

6.5.3.3. Gender-Specific Cases of Hepatic Encephalopathy in Italy

6.5.3.4. Age-Specific Cases of Hepatic Encephalopathy in Italy

6.5.3.5. Type-Specific Cases of Hepatic Encephalopathy in Italy

6.5.4. Spain

6.5.4.1. Assumptions and Rationale

6.5.4.2. Total Number of Hepatic Encephalopathy Cases in Spain

6.5.4.3. Gender-Specific Cases of Hepatic Encephalopathy in Spain

6.5.4.4. Age-Specific Cases of Hepatic Encephalopathy in Spain

6.5.4.5. Type-Specific Cases of Hepatic Encephalopathy in Spain

6.5.5. United Kingdom

6.5.5.1. Assumptions and Rationale

6.5.5.2. Total Number of Hepatic Encephalopathy Cases in the United Kingdom

6.5.5.3. Gender-Specific Cases of Hepatic Encephalopathy in the United Kingdom

6.5.5.4. Age-Specific Cases of Hepatic Encephalopathy in the United Kingdom

6.5.5.5. Type-Specific Cases of Hepatic Encephalopathy in the United Kingdom

6.6. Japan

6.6.1. Assumptions and Rationale

6.6.2. Total Number of Hepatic Encephalopathy Cases in Japan

6.6.3. Gender-Specific Cases of Hepatic Encephalopathy in Japan

6.6.4. Age-Specific Cases of Hepatic Encephalopathy in Japan

6.6.5. Type-Specific Cases of Hepatic Encephalopathy in Japan

7. Patient Journey

8. KOL Views

9. Appendix

9.1. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

List of Table

Table 1: Summary of Hepatic Encephalopathy (HE) Epidemiology (2018–2030)

Table 2: Clinical Description of Hepatic Encephalopathy (Adapted from AASLD-EASL Guideline 2014

Table 3: West Haven Criteria for hepatic encephalopathy and symptoms

Table 4: Stages of Hepatic Encephalopathy (HE)

Table 5: Total Number of Hepatic Encephalopathy Cases in the 7MM (2018–2030)

Table 6: Total Number of Hepatic Encephalopathy Cases in the United States (2018–2030)

Table 7: Gender-Specific Cases of Hepatic Encephalopathy in the United States (2018–2030)

Table 8: Age-specific Cases of Hepatic Encephalopathy in the United States (2018–2030)

Table 9: Type-Specific Cases of Hepatic Encephalopathy in the United States (2018–2030)

Table 10: Total Number of Hepatic Encephalopathy Cases in Germany (2018–2030)

Table 11: Gender-Specific Cases of Hepatic Encephalopathy in Germany (2018–2030)

Table 12: Age-Specific Cases of Hepatic Encephalopathy in Germany (2018–2030)

Table 13: Type-Specific Cases of Hepatic Encephalopathy in Germany (2018–2030)

Table 14: Total Number of Hepatic Encephalopathy Cases in France (2018–2030)

Table 15: Gender-Specific Cases of Hepatic Encephalopathy in France (2018–2030)

Table 16: Age-Specific Cases of Hepatic Encephalopathy in France (2018–2030)

Table 17: Type-Specific Cases of Hepatic Encephalopathy in France (2018–2030)

Table 18: Total Number of Hepatic Encephalopathy Cases in Italy (2018–2030)

Table 19: Gender-Specific Cases of Hepatic Encephalopathy in Italy (2018–2030)

Table 20: Age-Specific Cases of Hepatic Encephalopathy in Italy (2018–2030)

Table 21: Type-Specific Cases of Hepatic Encephalopathy in Italy (2018–2030)

Table 22: Total Number of Hepatic Encephalopathy Cases in Spain (2018–2030)

Table 23: Gender-Specific Cases of Hepatic Encephalopathy in Spain (2018–2030)

Table 24: Age-Specific Cases of Hepatic Encephalopathy in Spain (2018–2030)

Table 25: Type-Specific Cases of Hepatic Encephalopathy in Spain (2018–2030)

Table 26: Total Number of Hepatic Encephalopathy Cases in the United Kingdom (2018–2030)

Table 27: Gender-Specific Cases of Hepatic Encephalopathy in the United Kingdom (2018–2030)

Table 28: Age-Specific Cases of Hepatic Encephalopathy in the United Kingdom (2018–2030)

Table 29: Type-Specific Cases of Hepatic Encephalopathy in the United Kingdom (2018–2030)

Table 30: Total Number of Hepatic Encephalopathy Cases in Japan (2018–2030)

Table 31: Gender-Specific Cases of Hepatic Encephalopathy in Japan (2018–2030)

Table 32: Age-Specific Cases of Hepatic Encephalopathy in Japan (2018–2030)

Table 33: Type-Specific Cases of Hepatic Encephalopathy in Japan (2018–2030)

List of Figures

Figure 1: Symptoms of Hepatic Encephalopathy

Figure 2: Grading of the symptoms of Hepatic Encephalopathy

Figure 3: Risk Factors of Hepatic Encephalopathy

Figure 4: Pathophysiology of hepatic encephalopathy

Figure 5: Ammonia trafficking in hepatic encephalopathy (HE) from an organism (left panel) and an organ (right panel) perspective

Figure 6: The classification of HE, adapted from Amodio et al.

Figure 7: Total Number of Hepatic Encephalopathy Cases in the 7MM (2018–2030)

Figure 8: Total Number of Hepatic Encephalopathy Cases in the United States (2018–2030)

Figure 9: Gender-specific Cases of Hepatic Encephalopathy in the United States (2018–2030)

Figure 10: Age-specific Cases of Hepatic Encephalopathy in the United States (2018–2030)

Figure 11: Type-Specific Cases of Hepatic Encephalopathy in the United States (2018–2030)

Figure 12: Total Number of Hepatic Encephalopathy Cases in Germany (2018–2030)

Figure 13: Gender-Specific Cases of Hepatic Encephalopathy in Germany (2018–2030)

Figure 14: Age-Specific Cases of Hepatic Encephalopathy in Germany (2018–2030)

Figure 15: Type-Specific Cases of Hepatic Encephalopathy in Germany (2018–2030)

Figure 16: Total Number of Hepatic Encephalopathy Cases in France (2018–2030)

Figure 17: Gender-Specific Cases of Hepatic Encephalopathy in France (2018–2030)

Figure 18: Age-Specific Cases of Hepatic Encephalopathy in France (2018–2030)

Figure 19: Type-Specific Cases of Hepatic Encephalopathy in France (2018–2030)

Figure 20: Total Number of Hepatic Encephalopathy Cases in Italy (2018–2030)

Figure 21: Gender-Specific Cases of Hepatic Encephalopathy in Italy (2018–2030)

Figure 22: Age-Specific Cases of Hepatic Encephalopathy in Italy (2018–2030)

Figure 23: Type-Specific Cases of Hepatic Encephalopathy in Italy (2018–2030)

Figure 24: Total Number of Hepatic Encephalopathy Cases in Spain (2018–2030)

Figure 25: Gender-Specific Cases of Hepatic Encephalopathy in Spain (2018–2030)

Figure 26: Age-Specific Cases of Hepatic Encephalopathy in Spain (2018–2030)

Figure 27: Type-Specific Cases of Hepatic Encephalopathy in Spain (2018–2030)

Figure 28: Total Number of Hepatic Encephalopathy Cases in the United Kingdom (2018–2030)

Figure 29: Gender-Specific Cases of Hepatic Encephalopathy in the United Kingdom (2018–2030)

Figure 30: Age-Specific Cases of Hepatic Encephalopathy in the United Kingdom (2018–2030)

Figure 31: Type-Specific Cases of Hepatic Encephalopathy in the United Kingdom (2018–2030)

Figure 32: Total Number of Hepatic Encephalopathy Cases in Japan (2018–2030)

Figure 33: Gender-Specific Cases of Hepatic Encephalopathy in Japan (2018–2030)

Figure 34: Age-Specific Cases of Hepatic Encephalopathy in Japan (2018–2030)

Figure 35: Type-Specific Cases of Hepatic Encephalopathy in Japan (2018–2030)

  • Tags:
  • Hepatic Encephalopathy Epidemiology
  • Hepatic Encephalopathy
  • Hepatic Encephalopathy Pipeline
  • Hepatic Encephalopathy Companies
  • Hepatic Encephalopathy prevalent p...
  • Hepatic Encephalopathy incident po...
  • Hepatic Encephalopathy patients di...
  • Hepatic Encephalopathy treatment a...

Forward to Friend

Need A Quote